JP2021151253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021151253A5 JP2021151253A5 JP2021099897A JP2021099897A JP2021151253A5 JP 2021151253 A5 JP2021151253 A5 JP 2021151253A5 JP 2021099897 A JP2021099897 A JP 2021099897A JP 2021099897 A JP2021099897 A JP 2021099897A JP 2021151253 A5 JP2021151253 A5 JP 2021151253A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mammalian cell
- set forth
- sequence set
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004962 mammalian cell Anatomy 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 6
- 241000699800 Cricetinae Species 0.000 claims 3
- 230000001605 fetal effect Effects 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023018535A JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487550P | 2017-04-20 | 2017-04-20 | |
| US62/487,550 | 2017-04-20 | ||
| JP2019551563A JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551563A Division JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018535A Division JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021151253A JP2021151253A (ja) | 2021-09-30 |
| JP2021151253A5 true JP2021151253A5 (cg-RX-API-DMAC7.html) | 2021-12-09 |
| JP7227312B2 JP7227312B2 (ja) | 2023-02-21 |
Family
ID=62111232
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551563A Active JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
| JP2021099897A Active JP7227312B2 (ja) | 2017-04-20 | 2021-06-16 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
| JP2023018535A Active JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551563A Active JP6900500B2 (ja) | 2017-04-20 | 2018-04-16 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018535A Active JP7532571B2 (ja) | 2017-04-20 | 2023-02-09 | 抗N3pGluアミロイドベータペプチド抗体およびその使用 |
Country Status (28)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白-β之抗體及其用途 |
| TWI789644B (zh) * | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
| SG11202110504XA (en) | 2019-03-26 | 2021-10-28 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| WO2021151011A2 (en) * | 2020-01-24 | 2021-07-29 | The Board Of Trustees Of Western Michigan University | Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof |
| PE20231507A1 (es) * | 2020-10-02 | 2023-09-26 | Lilly Co Eli | Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped |
| TWI843040B (zh) | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| JP7306746B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7268910B2 (ja) * | 2021-09-16 | 2023-05-08 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| JP7306745B2 (ja) * | 2021-09-16 | 2023-07-11 | 株式会社ユニバーサルエンターテインメント | 遊技機 |
| MX2024004514A (es) * | 2021-10-22 | 2024-05-07 | Lilly Co Eli | Terapia de combinacion con el inhibidor de o-glcnacasa (oga). |
| CA3236560A1 (en) | 2021-10-29 | 2023-05-04 | Marcio Chedid | Compounds and methods targeting interleukin-34 |
| MX2024005144A (es) | 2021-10-29 | 2024-05-13 | Lilly Co Eli | Compuestos y metodos dirigidos a la interleucina-34. |
| US20260125460A1 (en) | 2021-10-29 | 2026-05-07 | Eli Lilly And Company | Compounds and methods targeting interleukin-34 |
| IL312380A (en) | 2021-10-29 | 2024-06-01 | Lilly Co Eli | Compounds and methods targeting interleukin-34 |
| CA3243602A1 (en) | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
| CN117327168B (zh) * | 2022-06-24 | 2026-06-19 | 厦门大学 | B2M-GluN1封闭肽、其药物组合物及用途 |
| CN120583962A (zh) * | 2022-11-17 | 2025-09-02 | 伊莱利利公司 | 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途 |
| WO2024133925A1 (en) | 2022-12-22 | 2024-06-27 | Bioarctic Ab | Antibody which binds to abetape3 |
| IL328051A (en) | 2023-11-14 | 2026-06-01 | Lilly Co Eli | Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES |
| WO2025228316A1 (en) * | 2024-04-28 | 2025-11-06 | Jacobio Pharmaceuticals Co., Ltd. | Anti-n3pglu amyloid beta antibodies and uses thereof |
| WO2025255300A1 (en) * | 2024-06-06 | 2025-12-11 | Eli Lilly And Company | FORMULATIONS FOR ANTI-N3pGlu AMYLOID BETA ANTIBODIES |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
| CN118459583B (zh) * | 2024-07-11 | 2024-09-10 | 齐鲁制药有限公司 | 抗N3pGlu淀粉样蛋白β抗体及其用途 |
| WO2026012421A1 (zh) * | 2024-07-11 | 2026-01-15 | 齐鲁制药有限公司 | 抗N3pGlu淀粉样蛋白β抗体及其用途 |
| WO2026075947A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Dosing regimens for early alzheimer's disease |
| WO2026122407A1 (en) * | 2024-12-04 | 2026-06-11 | Merck Sharp & Dohme Llc | Amyloid beta binder, and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006606B1 (ru) * | 2000-02-24 | 2006-02-24 | Вашингтон Юниверсити | Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения |
| US6815175B2 (en) * | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| WO2004013172A2 (en) | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
| AU2005290250A1 (en) | 2004-07-30 | 2006-04-06 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
| PE20061323A1 (es) * | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
| RU2498999C2 (ru) | 2006-07-14 | 2013-11-20 | Ац Иммуне Са | Гуманизированное антитело к амилоиду бета |
| CA2723995A1 (en) | 2008-06-12 | 2009-12-17 | Affiris Ag | Compounds for treating symptoms associated with parkinson's disease |
| WO2010004434A2 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
| KR101706789B1 (ko) | 2008-07-21 | 2017-02-14 | 프로비오드룩 아게 | 진단용 항체 검사법 |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| SI3339323T1 (sl) * | 2010-08-12 | 2019-12-31 | Eli Lilly And Company | Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe |
| WO2015175769A1 (en) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| JOP20170004B1 (ar) * | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
| TWI789644B (zh) * | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗-N3pGlu類澱粉β肽抗體及其用途 |
-
2018
- 2018-04-09 TW TW109140166A patent/TWI789644B/zh active
- 2018-04-09 TW TW107112023A patent/TWI705975B/zh active
- 2018-04-09 AR ARP180100882A patent/AR111208A1/es unknown
- 2018-04-16 MA MA050144A patent/MA50144A/fr unknown
- 2018-04-16 US US15/953,716 patent/US10647759B2/en active Active
- 2018-04-16 EA EA201992163A patent/EA201992163A1/ru unknown
- 2018-04-16 KR KR1020197030416A patent/KR102352670B1/ko active Active
- 2018-04-16 MX MX2019012445A patent/MX2019012445A/es unknown
- 2018-04-16 JO JOP/2019/0247A patent/JOP20190247A1/ar unknown
- 2018-04-16 BR BR112019018810A patent/BR112019018810A2/pt unknown
- 2018-04-16 CR CR20190445A patent/CR20190445A/es unknown
- 2018-04-16 CN CN201880025982.6A patent/CN110582511B/zh active Active
- 2018-04-16 CA CA3058482A patent/CA3058482C/en active Active
- 2018-04-16 NZ NZ758066A patent/NZ758066A/en unknown
- 2018-04-16 PE PE2019002050A patent/PE20200011A1/es unknown
- 2018-04-16 UA UAA201910202A patent/UA126806C2/uk unknown
- 2018-04-16 JP JP2019551563A patent/JP6900500B2/ja active Active
- 2018-04-16 SG SG11201909022P patent/SG11201909022PA/en unknown
- 2018-04-16 KR KR1020227001314A patent/KR102567295B1/ko active Active
- 2018-04-16 EP EP18722325.0A patent/EP3612559A1/en active Pending
- 2018-04-16 AU AU2018255221A patent/AU2018255221B2/en active Active
- 2018-04-16 CN CN202310757235.4A patent/CN117024583A/zh active Pending
- 2018-04-16 WO PCT/US2018/027718 patent/WO2018194951A1/en not_active Ceased
- 2018-04-16 IL IL269003A patent/IL269003B2/en unknown
-
2019
- 2019-09-18 ZA ZA2019/06159A patent/ZA201906159B/en unknown
- 2019-09-20 DO DO2019000241A patent/DOP2019000241A/es unknown
- 2019-10-14 CL CL2019002922A patent/CL2019002922A1/es unknown
- 2019-10-15 CO CO2019011349A patent/CO2019011349A2/es unknown
- 2019-10-16 SA SA519410311A patent/SA519410311B1/ar unknown
- 2019-10-17 MX MX2022011817A patent/MX2022011817A/es unknown
- 2019-10-17 PH PH12019502361A patent/PH12019502361A1/en unknown
- 2019-10-18 EC ECSENADI201975146A patent/ECSP19075146A/es unknown
-
2020
- 2020-04-08 US US16/843,503 patent/US11078261B2/en active Active
- 2020-12-17 ZA ZA2020/07868A patent/ZA202007868B/en unknown
-
2021
- 2021-06-14 AU AU2021203927A patent/AU2021203927B2/en active Active
- 2021-06-16 JP JP2021099897A patent/JP7227312B2/ja active Active
- 2021-08-02 US US17/391,821 patent/US20210371509A1/en not_active Abandoned
-
2023
- 2023-02-09 JP JP2023018535A patent/JP7532571B2/ja active Active